Suppr超能文献

孕激素治疗在妊娠中的作用:阴道和肌肉给药。

The effects of progesterone therapy in pregnancy: vaginal and intramuscular administration.

机构信息

Maternal, Fetal and Neonatal Research Center, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Growth and Developmental Research Center, Children Medical Center of Excellence, Tehran University of Medical Science, Tehran, Iran.

出版信息

J Matern Fetal Neonatal Med. 2021 Jul;34(13):2033-2040. doi: 10.1080/14767058.2019.1656190. Epub 2019 Aug 28.

Abstract

AIM

This study was performed to evaluate the effects of vaginal versus intramuscular progesterone supplementations on the mood, quality of life, and metabolic changes in pregnant women with the history of previous preterm birth.

METHODS

This study was conducted as a prospective, randomized, open label, clinical trial evaluated 100 pregnant women who referred for prenatal visit, with 16-17 weeks of gestation from September 2014 through October 2015. The mothers were then randomly allocated into two groups: the vaginal progesterone group to receive 400 mg cyclogest vaginal suppositories (Actavis, UK limited, England) once daily, and the intramuscular progesterone group to receive weekly intramuscular injections of 250 mg of 17-hydroxyprogesterone caproate (17-HPC) (Bayer Schering Pharma, Germany), starting from the 16th to the 35th weeks of pregnancy. Demographics, medical and obstetrical history, sleeping disturbances, alteration in sexual desire, nausea/vomiting, serum levels of fasting blood sugar (FBS), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were evaluated, first and 8 weeks later.

RESULTS

About 11 (11.2%) screened positive for psychosocial disorders; 25 (25.5%) had sleep disturbance, 11 (11.2%) had alteration in sexual desire, and 29 (29.6%) had nausea/vomiting upon enrollment. After 2 months of receiving daily vaginal progesterone, there was a significant increase in the GHQ-28 score ( < .001), and rates of positive screening for psychosocial disorders ( = .001) in this group. No statistically significant differences were observed in the HDL levels ( = .06), LDL levels ( = .15), rates of impaired FBS ( = .08), nausea/vomiting ( = .2), sexual desire alteration ( = .56), and sleep disturbance ( = 1) in the participants who were randomized to this group.

CONCLUSION

Our results indicated that psychosocial disorders increased significantly at 24th week gestational age after 2 months of progesterone consumption in both groups which could show psychological impact of progesterone regardless of the route of consumption. This calls for higher psychological attention in these women.

摘要

目的

本研究旨在评估阴道与肌肉注射黄体酮补充剂对有早产史的孕妇情绪、生活质量和代谢变化的影响。

方法

本研究为前瞻性、随机、开放标签临床试验,评估了 2014 年 9 月至 2015 年 10 月期间 100 名就诊于产前检查、妊娠 16-17 周的孕妇。随后,母亲们被随机分为两组:阴道黄体酮组每天接受 400mg 环丙孕酮阴道栓剂(Actavis,英国有限公司,英格兰)一次,肌肉黄体酮组从妊娠第 16 周到第 35 周每周接受 250mg 17-羟孕酮己酸酯(17-HPC)(Bayer Schering Pharma,德国)肌肉注射。评估人口统计学、医疗和产科史、睡眠障碍、性欲改变、恶心/呕吐、空腹血糖(FBS)、高密度脂蛋白(HDL)和低密度脂蛋白(LDL)水平,首次评估在第 1 周,第 8 周后再次评估。

结果

约有 11 名(11.2%)筛查出患有精神障碍;25 名(25.5%)有睡眠障碍,11 名(11.2%)有性欲改变,29 名(29.6%)在入组时出现恶心/呕吐。接受每日阴道黄体酮治疗 2 个月后,GHQ-28 评分显著升高( < .001),该组精神障碍筛查阳性率也显著升高( = .001)。在该组中,HDL 水平( = .06)、LDL 水平( = .15)、FBS 受损率( = .08)、恶心/呕吐( = .2)、性欲改变( = .56)和睡眠障碍( = 1)无统计学差异。

结论

我们的结果表明,两组在接受黄体酮治疗 2 个月后,在 24 周妊娠时,精神障碍显著增加,这表明无论使用哪种途径,黄体酮都会对心理产生影响。这就需要对这些女性给予更高的心理关注。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验